We are live on
!
Find out more
BG
Bellevue Group Portfolio holdings
AUM
$4.75B
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+5.04%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$6.97B
AUM Growth
-$106M
(-1.5%)
Cap. Flow
-$271M
Cap. Flow
% of AUM
-3.88%
Top 10 Holdings %
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$28.5M |
| 2 |
Celldex Therapeutics
CLDX
|
+$26.8M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$15.3M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$13.7M |
| 5 |
Charles River Laboratories
CRL
|
+$6.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
+$91.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$38.7M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$24M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$19.3M |
| 5 |
Axsome Therapeutics
AXSM
|
+$16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0.59% |
| 3 | Miscellaneous | 0.03% |
| 4 | Energy | 0.02% |
| 5 | Communication Services | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
United Microelectronic
UMC
$52.1B
| $15K | ﹤0.01% |
+2,698
| New | +$17.8K |
|
177
Alkermes
ALKS
$7.73B
| – | – |
-107,200
| Closed | -$3.19M |
|
178
Arcturus Therapeutics
ARCT
$450M
| – | – |
-39,550
| Closed | -$623K |
|
179
Health Catalyst
HCAT
$127M
| – | – |
-424,611
| Closed | -$6.15M |
|
180
Kura Oncology
KURA
$1.18B
| – | – |
-63,700
| Closed | -$1.17M |
|
181
NovoCure
NVCR
$2.09B
| – | – |
-25,300
| Closed | -$1.76M |
|
182
Pacira BioSciences
PCRX
$1.05B
| – | – |
-51,936
| Closed | -$3.03M |
|
183
Ultragenyx Pharmaceutical
RARE
$1.51B
| – | – |
-31,000
| Closed | -$1.85M |
|
|
SLN
184
Silence Therapeutics
SLN
$907M
| – | – |
-30,483
| Closed | -$361K |
|
185
Sanofi
SNY
$106B
| – | – |
-42,300
| Closed | -$2.12M |
|
|
ONEM
186
DELISTED
1Life Healthcare
ONEM
| – | – |
-836,190
| Closed | -$6.56M |
|
|
RDUS
187
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-8,796,538
| Closed | -$91.2M |
|
Similar funds
SP
GS
SAMU
LPPI
VFA
NHC
PTC
KCM
Bellevue Group's Q3 2022 Portfolio in Review
As of Q3 2022, Bellevue Group held 187 positions worth $6.97B, down 1.5% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Bellevue Group withdrew a net $271M in Q3 2022, closing 11 positions and reducing 87 holdings. Its most notable exit was Radius Health, Inc., an estimated $91.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Miscellaneous.
Against the trend, Bellevue Group opened a new position in Zai Lab worth $1.28M.
- Bellevue Group's largest Q3 2022 buy was Zai Lab: 36,600 shares worth $1.28M.
- Bellevue Group added most to Revolution Medicines in Q3 2022, an estimated $28.5M increase.
- Bellevue Group's biggest Q3 2022 reduction was Sarepta Therapeutics, cutting an estimated $38.7M.
- Bellevue Group fully exited Radius Health, Inc. in Q3 2022, selling an estimated $91.2M.
- Bellevue Group's ten largest holdings make up 35% of its $6.97B portfolio in Q3 2022.
- Bellevue Group opened 15 new positions and closed 11 in Q3 2022.
- Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $6.97B.
Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.